Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

Rhea-AI Summary

Prelude Therapeutics (Nasdaq: PRLD) announced participation in two virtual investor conferences: the 42nd Annual Goldman Sachs Global Healthcare Conference with a fireside chat on June 9, 2021, at 8:00 a.m. ET, and the JMP Securities Life Sciences Conference on June 16, 2021, at 10:00 a.m. ET. Live webcasts will be available on the company's website, with replays for a limited time. Prelude focuses on precision oncology with notable candidates like PRT543 for advanced solid tumors and PRT811 for glioblastoma.

WILMINGTON, Del., June 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences:

• 42^nd Annual Goldman Sachs Global Healthcare Conference
  

Fireside chat at 8:00 a.m. ET on Wednesday, June 9, 2021

• JMP Securities Life Sciences Conference
  

Corporate presentation at 10:00 a.m. ET on Wednesday, June 16, 2021

A live webcast of the Goldman Sachs fireside chat and JMP Securities presentation can be accessed under “Events & Presentations” in the Investor Section of the Company’s website, https://investors.preludetx.com/news-and-events/events-and-presentations, where a replay of the events will also be available for a limited time.

About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.

Contact

Investors: Melissa Forst
Media: Deborah Elson
Argot Partners
212.600.1902
prelude@argotpartners.com

FAQ

What are the details of Prelude Therapeutics' participation in the Goldman Sachs Global Healthcare Conference?

Prelude Therapeutics will participate in the 42nd Annual Goldman Sachs Global Healthcare Conference with a fireside chat on June 9, 2021, at 8:00 a.m. ET.

When will Prelude Therapeutics present at the JMP Securities Life Sciences Conference?

Prelude Therapeutics will present at the JMP Securities Life Sciences Conference on June 16, 2021, at 10:00 a.m. ET.

Where can I watch the live webcasts of Prelude Therapeutics' conferences?

The live webcasts of Prelude Therapeutics' conferences can be accessed on their website under 'Events & Presentations'.

What are the key drug candidates being developed by Prelude Therapeutics?

Prelude Therapeutics is developing notable candidates like PRT543 for advanced solid tumors and PRT811 for glioblastoma multiforme.

Is there a replay available for the conferences held by Prelude Therapeutics?

Yes, a replay of Prelude Therapeutics' conference presentations will be available for a limited time on their website.